Biotech Stock Tip: Make the Most of the “Novel” Drug Rush
In this episode of The Bull & The Bear, we examine how novel drug approvals can impact biotech stocks like ...
Podcast
Don’t Count on Biogen Stock Gains — Alzheimer’s Drug Has Baggage
In this episode of The Bull & The Bear, I tell you if Biogen stock (Nasdaq: BIIB) is a buy ...
Find Profits as Prices Surge — Your “Shortage Economy” Guide
In this week's episode of The Bull & The Bear, Adam, Charles and I look at how to approach investing ...
Meme Stock Mania: AMC’s Meteoric Rise and a Huge Red Flag
Social media activity has pushed "meme" stocks like AMC and GME to incredible heights. But there's a problem with following ...
This Isn’t the May to “Go Away” — Here’s Why
In this episode of The Bull & The Bear, Adam O'Dell and I tell you why this might not be ...
Hold or Fold 4 Sports Betting Stocks as Industry Eyes $8B Future
Sports gambling is becoming a huge and profitable industry. In this episode of The Bull & The Bear, I look ...
Buy, Hold or Walk Away: AT&T’s $43B Move Triggers One Signal
In this episode of The Bull & The Bear, Charles Sizemore and I tell you where we think AT&T stock ...
The Great Crypto Crash: What to Do After Bitcoin’s 40% Fall
In this episode of The Bull & The Bear, I dive into bitcoin after a tweet from Tesla CEO Elon ...
Biotech’s 30% Dip: Your Entry Point Into a Future Top Trend
In this episode of The Bull & The Bear, we tell you where we think biotech stocks are headed after ...
What a Gas! Pipeline Panic Won’t Fuel a Stock Crash
In this episode of The Bull & The Bear, I break down the Colonial Pipeline situation and what it means ...
